About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
BPMC - Blueprint Medicines ...| Previous Close | $88.00 | Open | $88.30 |
| Volume | 411.2K | Market Cap | 4.864B |
| Yield | Last Dividend |
| Blueprint Medicines Reports ARROW Trial ... | 09/20/20 |
| CAMBRIDGE, Mass., Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically de... | |
| Blueprint Medicines Presents Foundationa... | 09/17/20 |
| CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically de... | |
| Blueprint Medicines to Present at 18th A... | 09/09/20 |
| CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defi... | |
| Roche, Blueprint lung cancer drug wins F... | 09/04/20 |
| Roche Holding AG on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp was approved by the U.S. health regulator ??? | |
| Blueprint Medicines Announces FDA Approv... | 09/04/20 |
| CAMBRIDGE, Mass., Sept. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| Blueprint Medicines Strengthens Leadersh... | 09/01/20 |
| CAMBRIDGE, Mass., Sept. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| Blueprint Medicines Reports Second Quart... | 07/30/20 |
| CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defi... | |
| Blueprint Medicines Receives Positive CH... | 07/24/20 |
| CAMBRIDGE, Mass., July 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| Blueprint Medicines to Report Second Qua... | 07/23/20 |
| CAMBRIDGE, Mass., July 23, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| What Does $1.7 Billion Mean to Blueprint... | 07/14/20 |
| No summary available. | |
| The Daily Biotech Pulse: Blueprint, Roch... | 07/14/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Alt... | |
| Blueprint Medicines partners with Roche ... | 07/14/20 |
| Blueprint Medicines is partnering with Roche to develop and market a cancer drug near approval for use in patients with tumors with a genetic mutation... | |
| Roche teams up with Blueprint Medicines ... | 07/14/20 |
| Building on their 2016 partnership aimed at developing up to five kinase inhibitors in cancer, Roche (OTCQX:RHHBY) and Blueprint Medicines (NASDAQ:BPM... | |
| Roche gene testing key to $1.7 billion d... | 07/14/20 |
| Roche has struck a $1.7 billion cancer drug pact with Blueprint Medicines, it said on Tuesday, as advances in genetic testing for rare mutations drive... | |
| Roche to pay Blueprint up to $1.7 billio... | 07/14/20 |
| Swiss drugmaker Roche on Tuesday struck a deal worth up to $1.7 billion with Blueprint Medicines to develop and commercialise a new treatment for peop... | |
| Blueprint Medicines : Announces Global C... | 07/14/20 |
| CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation , a precision therapy company focused on genomically defined cancers, ... | |
| Blueprint Medicines Announces Global Col... | 07/14/20 |
| CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| Blueprint Medicines Announces Submission... | 07/01/20 |
| CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defi... | |
| Blueprint Medicines Announces Publicatio... | 06/29/20 |
| CAMBRIDGE, Mass. , June 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC ), a precision therapy company focused on genomically d... | |
| Blueprint Medicines Presents Updated Par... | 06/06/20 |
| CAMBRIDGE, Mass., June 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defi... | |
| Blueprint Medicines (BPMC) Up 15.5% Sinc... | 06/05/20 |
| Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Blueprint Medicines Announces Data Prese... | 05/29/20 |
| CAMBRIDGE, Mass., May 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defi... | |
| Blueprint Medicines to Host Conference C... | 05/26/20 |
| CAMBRIDGE, Mass., May 26, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defin... | |
| Blueprint Medicines Gets CRL for Ayvakit... | 05/18/20 |
| The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST. | |
| Blueprint Medicines Receives Complete Re... | 05/15/20 |
| CAMBRIDGE, Mass., May 15, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defi... | |
| All You Need to Know About Blueprint Med... | 05/14/20 |
| Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (B... | |
| How Blueprint Medicines (BPMC) Stock Sta... | 05/12/20 |
| Blueprint Medicines (BPMC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| Strong Buy rating | 07/27/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $106.00 to $107.00 | |
| Buy rating | 07/15/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $66.00 to $110.00 | |
| Strong Buy rating | 07/15/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $105.00 to $106.00 | |
| Strong Buy rating | 07/15/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $88.00 to $92.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
